Publication | Closed Access

Potentiation of the effect of gemcitabine by emodin in pancreatic cancer is associated with survivin inhibition

Pancreatic CancerMedicinePharmacologyPharmacotherapyAnti-cancer AgentCancer TreatmentSurvivin InhibitionOncologyCell BiologyCancer Research